AstraZeneca Purchases US Biologics Manufacturing Facility to Support Growing Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AstraZeneca (AZN) Acquires Biologics Manufacturing Facility from Amgen (AMGN)
September 11, 2015 7:02 AM EDTAstraZeneca (NYSE: AZN) added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc (Nasdaq: AMGN). Over time, the LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the companys extensive portfolio of biologics medicines.
AstraZeneca plans to start staffing the facility immediately to... More
